Skip to main content
. 2017 Dec 8;9(12):10360–10374. doi: 10.18632/oncotarget.23164

Figure 5. CPX monotherapy improves the efficacy of gemcitabine monotherapy on the growth of established local pancreatic tumors in BxPC-3 Panc1 and MIA PaCa-2 xenograft models.

Figure 5

(A) SCID mice were implanted with BxPC-3 Panc1 and MIA PaCa-2 cells. When local tumors were established, animals were randomly subdivided into four groups (i) vehicle; (ii) Gemcitabine alone (60 mg/kg); (iii) CPX alone (25 mg/kg); (iv) Combination of gemcitabine (60 mg/kg) and CPX (25mg/kg) of each cancer cell line, respectively. The animals were continuously gavaged with the agents for 90 days as mentioned in the Materials and Methods section. The tumor volume within each treatment group was calculated (thrice/per week) and presented in the indicated graphs. Values are means, n = 6–8. *Significant difference (P < 0.05), **Significant difference (P < 0.01) versus controls. Combination therapy was significantly more potent and the difference reached significance compared with gemcitabine treatment alone after 31 days for MIA PaCa-2 and 35 days for BxPC-3 and 46 days Panc1 (#P < 0.05 Student's t-test). (B) The median survival of BxPC-3, Panc1 and MIA PaCa-2 pancreatic tumors in each treatment group was constructed according to the Kaplan-Meier survival curve; n = 6 mice in each sub –group. The P values (*P, 0.05, **P, 0.01 vs the control group) for survival differences were determined applying log-rank testing (GraphPad Prism 4). CTR, vehicle control; Gemci, Gemcitabine; CPX, ciclopirox.